Insurance parity bill would restrict utilization management and require treatment consistent with clinical standards, OIC estimates enforcement cost

Engrossed Second Substitute House Bill 14 32 would strengthen enforcement of mental‑health and substance‑use disorder parity by requiring carriers to use generally accepted clinical standards and recognized patient-placement criteria for utilization-review decisions.

Among the bill’s provisions are: a requirement that carriers (and their pharmacy/behavioral health managers) offer “meaningful benefits” covering standard treatment for diagnosed conditions; a prohibition on prior authorization and other utilization-management reviews for the initial evaluation and up to six consecutive outpatient visits for mental health and SUD care; and a requirement that utilization- and placement decisions be based on age‑appropriate criteria published by nonprofit professional associations. The bill also codifies that medical‑surgical and behavioral health benefits must be comparable under parity rules.

The Office of the Insurance Commissioner (OIC) provided an updated fiscal note showing $1.264 million in one-time regulatory costs in 2025–27 for rulemaking, data collection and enforcement work. The updated note indicates the House-passed changes narrow impacts to public‑employee plans (PERS/SEBB) and removes direct cost impacts to those programs in the current fiscal estimate.

Advocates — including the National Alliance on Mental Illness (NAMI), mental‑health clinicians and other groups — argued the bill would reduce inappropriate denials, speed treatment starts and shift care away from emergency departments and publicly funded services. NAMI’s Anna Nepomissano told lawmakers that 60 percent of commercially insured Washingtonians with a diagnosed mental‑health condition did not receive treatment in the prior year, and that denials drive downstream public costs.

Insurer and employer representatives testified about potential implementation complexity and urged caution. They supported the bill’s intent to align coverage with clinical standards but warned about operational challenges and possible rate impacts depending on how clinical acceptability is specified and enforced.

Ending: The committee received a high volume of public testimony and OIC cost estimates; staff said the bill’s language had been narrowed in committee and emphasized continued coordination between OIC, carriers and providers to implement clinical‑standards requirements without unintended market disruption.